A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 6, 2000, Pages 2197-2202

  Prestwood, Karen M ^a   Gunness, Michele ^b   Muchmore, Douglas B ^c   Lu, Yili ^c   Wong, Mayme ^c   Raisz, Lawrence G ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; RALOXIFENE;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE METABOLISM; BONE MINERALIZATION; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; ILIAC CREST; MAJOR CLINICAL STUDY; MORPHOMETRICS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SUBSTITUTION THERAPY;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BIOPSY; BONE AND BONES; BONE DENSITY; CALCIUM, DIETARY; COLLAGEN; COLLAGEN TYPE I; CREATININE; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MIDDLE AGED; OSTEOCALCIN; PEPTIDE FRAGMENTS; PEPTIDES; POSTMENOPAUSE; PROCOLLAGEN; RALOXIFENE;

EQUIDAE;

EID: 0034455674     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.6.2197     Document Type: Article

References (32)

1. Overview of osteoporosis
2. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women
3. Osteoporosis: Pathogenesis, diagnosis and treatment in older adults
4. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
5. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study
6. Estrogen treatment of patients with established postmenopausal osteoporosis
7. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group
8. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
9. Hormone therapy to prevent disease and prolong life in postmenopausal women
10. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108411 women without breast cancer
11. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
12. Cinical effects of raloxifene hydrochloride in women
13. The effects of raloxifene on tibia histomorphometry in ovariectomized rats
14. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteoperda
15. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats
16. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
17. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HCl, tamoxifen, estrogen, and alendronate
18. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
19. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
20. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
21. Raloxifene mimics estrogen in human bone remodeling kinetics
22. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
23. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee
24. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis
25. The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women
26. The short-term effects of conjugated estrogen on bone turnover in older women
27. Low dose estrogen and calcium have an additive effect on bone resorption in older women
28. Treatment of postmenopausal osteoporosis with transdermal estrogen
29. Reduction of vertebral fracture risk in postmenopuasal women with osteoporosis treated with raloxifene
30. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
31. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs